Andreas Stolle, PhD, VP API Process development services, said this added a 300,000 sq. ft. facility with manufacturing capabilities for small molecule APIs from development to commercial manufacturing.
“Drugs are getting more and more complicated,” Andreas added. “So we also added some new technolgoy to our network,” including solid state chemistry, Micronization, and in the future, spray drying.
The site will serve as the company’s flagship US API operation for commercial small- and mid-scale API manufacturing
“We believe that the industry needs a simplified and integrated supply chain,” said Andreas. “And with this addition in our network we are able to serve the client much, much better.”